Friday, April 05, 2013 2:42:25 PM
Emergent BioSolutions to expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment and encouraging early clinical data (EBS) 13.41 : Co announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia (CLL). The expanded protocol will include two new study cohorts to examine a lower dose of TRU-016 with rituximab in front line CLL and to evaluate the combination in relapsed CLL patients. This decision is based on strong patient enrollment along with encouraging early safety and efficacy data from this study. TRU-016 is the co's humanized anti-CD37 monospecific protein therapeutic, built on its ADAPTIRTM (Modular Protein Technology) platform, for the treatment of CLL. The co anticipates that this expanded clinical program will significantly enhance the value of TRU-016 and the company's active partnering program without impacting the company's total 2013 operating expenses.
TRU-016 is also currently being evaluated in a randomized, open label, active-controlled Phase 2 study in combination with bendamustine in patients with relapsed CLL. This study is on track to achieve its target enrollment of approximately 60 patients in April 2013.
Recent EBS News
- Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024 • GlobeNewswire Inc. • 05/10/2024 11:17:04 AM
- Emergent BioSolutions Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 08:57:22 PM
- Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position • GlobeNewswire Inc. • 05/01/2024 08:10:00 PM
- Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone • GlobeNewswire Inc. • 05/01/2024 03:03:28 PM
- Emergent BioSolutions Announces Amendment to its Existing Credit Facility • GlobeNewswire Inc. • 04/30/2024 09:26:55 PM
- Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/22/2024 12:05:00 PM
- Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis • GlobeNewswire Inc. • 03/28/2024 12:15:03 PM
- Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility • GlobeNewswire Inc. • 03/25/2024 12:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 09:21:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:31:51 AM
- Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 03/06/2024 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:15:47 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:43:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:42:33 PM
- Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 01:30:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 01:28:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:25:51 PM
- Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 12:41:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:40:06 PM
- Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 • GlobeNewswire Inc. • 01/09/2024 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM